Literature DB >> 14981951

Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels.

Kazuhisa Matsumoto1, Kazuhiro Suzuki, Hidekazu Koike, Keigo Okamura, Kiyotaka Tsuchiya, Tatsuya Uchida, Yutaka Takezawa, Mikio Kobayashi, Hidetoshi Yamanaka.   

Abstract

BACKGROUND: Angiogenesis plays important roles in pathogenesis in human cancer. We assessed the relationship between clinical features of renal cell cancer (RCC) and PlGF levels in relation to VEGF.
MATERIALS AND METHODS: Plasma PlGF and VEGF levels were measured in patients with renal cell cancer. The levels of these angiogenetic factors were analyzed in relation to clinical parameters.
RESULTS: PlGF and VEGF levels in patients with RCC were significantly higher than those in non-cancer controls. PlGF levels were significantly associated with histological grade and total tumor vascularity (TTV), and VEGF levels were significantly associated with T, M stage, histological grade, venous invasion and TTV. Multivariate analysis showed plasma PlGF was an independent prognostic factor.
CONCLUSION: These findings suggested that plasma PlGF levels were significantly associated with the clinical features of RCC, especially prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14981951

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

Review 2.  Role of placenta growth factor in cancer and inflammation.

Authors:  Ki Jo Kim; Chul Soo Cho; Wan Uk Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

Review 3.  Perspectives in drug development for metastatic renal cell cancer.

Authors:  Bristi Basu; Tim Eisen
Journal:  Target Oncol       Date:  2010-08-06       Impact factor: 4.493

4.  Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer.

Authors:  Ming-Ming Hu; Ying Hu; Hai-Qing Zhang; Wen-Yun Jia; Zhe Qian; Yuan Yang; Bao-Lan Li
Journal:  Biomed Rep       Date:  2014-07-25

5.  Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer.

Authors:  Wei Huang; Shuli Zhu; Qiang Liu; Chanyu Li; Li Li
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

6.  [Therapeutic mechanism of natural astaxanthin against renal clear cell carcinoma based on network pharmacology and bioinformatics].

Authors:  J Gao; D Yang; R Cao; X Pan; J Xia
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-12-20

7.  Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.

Authors:  Nibal Zaghloul; Sonia L Hernandez; Jae-O Bae; Jianzhong Huang; Jason C Fisher; Alice Lee; Angela Kadenhe-Chiweshe; Jessica J Kandel; Darrell J Yamashiro
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

8.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

Review 9.  The role of angiogenic factors in endometrial cancer.

Authors:  Monika Magdalena Żyła; Marta Kostrzewa; Ewelina Litwińska; Artur Szpakowski; Jacek Radosław Wilczyński; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2014-05-21

10.  The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.

Authors:  Christopher H Lieu; Hai Tran; Zhi-Qin Jiang; Muling Mao; Michael J Overman; E Lin; Cathy Eng; Jeffrey Morris; Lee Ellis; John V Heymach; Scott Kopetz
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.